Why it costs $2.6 billion and takes 12 years to bring a drug to market—and what that means for compounds stuck in Phase II.

Sources and References

Related Guides

Quick Facts

The Pipeline: An Overview

Drug development follows a structured pathway with distinct gates. Each gate requires evidence before the compound advances. This is not bureaucratic obstruction—it is the accumulated wisdom of decades of medical disasters, each one preventable if earlier stages had been more rigorous.

The pipeline looks like this:

1. Discovery—Identify a compound worth investigating
2. Preclinical testing—Test it in cells and animals
3. IND application—Request FDA permission to test in humans
4. Phase I—Test safety in healthy volunteers (usually)
5. Phase II—Test whether it works in patient populations
6. Phase III—Confirm it works better than existing options, in large populations
7. NDA/BLA review—FDA reviews all the data
8. FDA approval—Compound gets a prescription label
9. Phase IV—Post-marketing surveillance for long-term safety

A compound can fail at any gate. In fact, most do. The attrition is brutal: roughly 10% of compounds that enter Phase I human testing ever reach FDA approval. The remaining 90% fall out for safety reasons, efficacy reasons, or because the cost-benefit calculation no longer makes sense.

The timeline is 10–15 years from discovery to approval for most small molecules and biologics. The cost averages $1–2 billion for a single approved drug, including the failed candidates and the overhead of running the entire system.

This is not theoretical. The FDA publishes these numbers. The Pharmaceutical Research and Manufacturers of America (PhRMA) documents the attrition rates. The pipeline is not faster or cheaper than this—the timeline and cost are the pipeline.

↑ Back to top

Discovery and Preclinical Testing

A drug begins as a hypothesis. Researchers identify a biological target—a receptor, an enzyme, a pathway—and reason that modulating it might treat a disease. They synthesize a compound or identify a natural molecule that does this. Then they test whether it works the way they predicted.

This is the preclinical phase, and it is entirely in the lab.

What Happens in Preclinical

In vitro testing—Researchers put the compound in a petri dish with cells from human tissue (or from animals, or cell lines grown in culture). They measure whether the compound binds to its target receptor, activates an enzyme, or produces a cellular response. This is fast and cheap. It can be done on thousands of compounds. It is also the furthest thing from proof that the compound will work in a human body.

In vitro experiments happen in isolation. They do not account for absorption (how the compound gets into the body), metabolism (how the body breaks it down), distribution (where it goes once it’s in the bloodstream), or excretion (how the body gets rid of it). They do not account for off-target effects—the compound might bind to 15 different receptors, and the cell culture test only looked at one. They do not account for the immune system, the nervous system’s regulatory mechanisms, or the thousand ways a living body is more complex than a petri dish.

This is not a flaw in in vitro testing. It is the nature of in vitro testing. It answers a narrow question well: “Does this compound interact with this protein the way we predicted?” Whether that interaction matters for human health is a different question.

Animal models—If the in vitro results are promising, researchers move to animals, usually rodents (rats or mice). They give the compound to the animal and measure whether it produces the intended effect. Does it lower blood glucose in diabetic mice? Does it reduce inflammation in a colitis model? Does it accelerate healing in a surgically induced tendon injury?

Animal models are vastly more complex than petri dishes. They include absorption, metabolism, distribution, excretion, immune responses, and the integrated physiology of a living organism. They are also vastly more predictive than petri dishes.

They are still not humans.

Why Animal Results Fail in Humans

The translation from animals to humans fails surprisingly often. The reasons are well-documented:

Pharmacokinetics differ. A compound that is absorbed quickly in rats may be absorbed slowly in humans. A compound that has a half-life of three hours in mice may have a half-life of 36 hours in humans (or vice versa). These differences mean different drug exposures and different effects.

Dosing scales differently. A dose that is safe and effective in a 200-gram mouse is not the same as a dose in a 70-kilogram human, even after accounting for body weight. Scaling across species is not straightforward. A compound’s metabolism, receptor density, and organ sensitivity all vary by species.

Pathology is not identical. Colitis in a mouse model is not the same disease as ulcerative colitis in a human. The models capture some features of human disease but not others. A compound might work beautifully in the model and fail to work in the actual disease because the relevant mechanisms are different.

Humans have additional complexity. Humans have comorbidities, concurrent medications, genetic variation, and immune histories that lab animals do not (or that researchers do not measure). A compound that works in genetically identical laboratory mice may fail in a genetically diverse human population.

Off-target effects emerge. In animal studies, researchers usually measure the intended outcome. They may not measure all the organ systems that the compound affects. Side effects that emerge in humans—kidney problems, liver problems, neurological effects—may not have been characterized in animals because the researchers didn’t look for them or because they manifest differently across species.

The consequence: Historical data show that about 90% of drugs that pass preclinical testing and enter Phase I human trials eventually fail. Some fail for safety reasons discovered in human testing. Some fail because they don’t work in humans the way they worked in animals. Some fail for both reasons.

This is the first gate, and it filters out the vast majority of compounds.

Preclinical Mechanistic Work: ADME and Toxicology

Before a compound reaches the IND application stage, preclinical researchers must characterize:

ADME—Absorption, Distribution, Metabolism, Excretion. How does the body process this compound? How much gets into the bloodstream? Where does it go? How is it broken down? How long does it stay in the body? These questions are answered in animal models and in test tube studies of human liver enzymes.

Toxicology—What damage does the compound cause at different doses? Is there a dose below which it causes no measurable harm? What organs does it damage (if any)? How reversible is the damage? In regulatory language, toxicology studies must follow Good Laboratory Practice (GLP) standards—standardized protocols, documented procedures, quality control, independent auditing. This is expensive and thorough, but it is mandatory before moving to human testing.

The preclinical toxicology studies are done in animals, usually rats and dogs (sometimes non-human primates for biologics). Researchers give the compound at multiple doses—a no-observed-adverse-effect level (NOAEL) and doses above it to determine where problems emerge—and measure effects on multiple organs. These studies last weeks to months.

The Attrition Reality

Only about 10% of the compounds that show promise in cell culture ever enter animal testing. Of those that do, only about 25% advance to the IND stage and human testing. So roughly 2–3% of compounds that show in vitro promise ever reach Phase I in humans.

This filter is intentional. It is also expensive—researchers screen thousands of compounds to find one worth taking to human trials. But this is the cost of a pipeline that works.

↑ Back to top

The IND Application: Permission to Test in Humans

An Investigational New Drug (IND) application is the formal request to the FDA for permission to test a new compound in humans. It is not a request for approval. It is a request to conduct research.

The IND application requires:

Chemistry and Manufacturing (CMC)—How is the compound made? What are its purity standards? How will it be manufactured consistently at scale? How will it be stored? This section proves that the compound can be manufactured reliably and that every batch will be consistent. For peptides, this includes characterization of the peptide sequence, post-translational modifications (if any), and stability under the proposed storage conditions.

Nonclinical (preclinical) data—All the animal and in vitro data. Mechanism of action. ADME studies. GLP toxicology studies. The IND application summarizes the preclinical portfolio and explains why this compound is worth testing in humans.

Clinical protocol—The plan for Phase I. How many people? What doses? What route (IV, subcutaneous, oral)? What safety monitoring? What stopping rules (what happens if someone has a serious adverse event)? How will you measure safety?

Investigator’s brochure—A document summarizing everything known about the compound, including the mechanism, the preclinical data, any prior human data (if from a foreign country or a published study), and known or predicted adverse effects.

IRB approval—An Institutional Review Board (IRB) must review the protocol and approve it as ethically sound before the IND application is submitted.

The FDA has 30 days to respond to an IND application. The agency can approve it (allowing the trial to proceed), request additional information, or reject it (blocking human testing until the issues are resolved).

This is the gate where most peptides used in the community never pass.

Why? Because an IND application requires GLP toxicology data, CMC data, and a detailed clinical protocol. It requires an institutional setting, IRB oversight, and regulatory coordination. It requires funding—a Phase I study can easily cost $500,000–$2 million. It requires willingness to operate within regulatory oversight. It requires a company or research institution with sufficient resources and regulatory infrastructure.

Most peptides are identified in academic labs and then picked up by compounding pharmacies. They never enter the IND pipeline. They never get the preclinical work characterized at GLP standards. The clinical data (if any) comes from open-label studies, small pilot trials, or retrospective case reports—not from controlled trials with regulatory oversight.

This is not a moral failing of the compounding pharmacy industry. It is a statement about the regulatory and financial barriers to IND applications. Those barriers exist to protect human subjects. They also mean that compounds operating outside the IND pipeline never accumulate evidence the way FDA-regulated compounds do.

↑ Back to top

Phase I: Safety and Pharmacokinetics

Phase I is the first time a compound is given to humans. The goal is not to prove the compound works. The goal is to determine whether it is safe enough to continue testing.

Phase I Design

Phase I trials are small—typically 20–80 healthy volunteers, though some Phase I trials in serious diseases include patients rather than healthy volunteers. The compound is given at escalating doses (called a dose escalation study). Researchers start at a very low dose and increase it until they see side effects or reach a predetermined maximum dose. Safety data is monitored closely. If a serious adverse event occurs, the trial may be paused or stopped.

Phase I also characterizes pharmacokinetics (PK)—how the body processes the drug. Researchers measure the drug concentration in the bloodstream over time. They determine the peak concentration, the time to peak, the half-life, and how the compound is metabolized and excreted. They also characterize pharmacodynamics (PD)—how the drug’s presence in the body changes biological markers.

Why Phase I Is Necessary

Phase I is where animal results often diverge from human reality. A compound might be well-tolerated in rats but cause serious nausea in humans. It might have a three-hour half-life in mice but a 36-hour half-life in humans. It might activate off-target receptors that animal studies missed.

Phase I also establishes the starting dose for Phase II. The maximum tolerated dose (MTD) or the highest dose that does not cause unacceptable side effects becomes the reference point for efficacy testing.

Ipamorelin as an Example

Ipamorelin is a good Peptidings example. Preclinical data (Raun et al., published studies) showed that ipamorelin stimulates growth hormone secretion in animals. The mechanism was well-characterized: ipamorelin acts as a ghrelin receptor agonist.

In 2004, Gobburu et al. published a Phase I pharmacokinetic and pharmacodynamic study of ipamorelin in healthy volunteers. The study characterized the PK/PD profile—how ipamorelin is absorbed, how long it circulates, and how it affects growth hormone levels in humans. This was the first controlled human data for ipamorelin.

That Phase I study did not prove ipamorelin is effective for muscle growth, fat loss, or recovery. It proved that ipamorelin can be given to humans at certain doses without unacceptable acute toxicity, and it characterized the human pharmacology.

Ipamorelin never advanced beyond Phase I. There are no Phase II or Phase III controlled trials of ipamorelin in any indication. This is why ipamorelin exists in Peptidings’ Tier 4 evidence tier: preclinical data plus a single Phase I safety study. No controlled trial has tested whether it actually works for the conditions people use it for.

↑ Back to top

Phase II: Does It Actually Work?

Phase II is where most drug candidates fail.

Phase I proved safety. Phase II tests efficacy—does the compound actually work in patients with the target condition?

Phase II Design

Phase II trials are larger than Phase I (typically 100–300 patients) and include people with the condition being treated. They are often dose-ranging studies—researchers test multiple doses to find the dose that produces the best balance of efficacy and side effects. Some Phase II trials are controlled (comparing the compound to placebo or to an existing treatment), and some are open-label (everyone knows they’re getting the investigational drug).

Phase II trials are measured against a specific endpoint—a change in a biomarker, a symptom score, or a clinical outcome. Researchers define the endpoint in advance and decide what magnitude of change would count as success.

Why Phase II Is the Gatekeeper

Phase II is where preclinical promise often fails to translate. A compound might have impressive mechanism of action and acceptable safety in Phase I, but simply not work well enough in the target disease. The effect might be too small to be clinically relevant. The duration might be too short. The side effects might be unacceptable in a sick population (different from healthy volunteers). Patient populations might be more heterogeneous than animal models, and the compound might work in some patients but not others.

Historically, about 70% of drugs that enter Phase II fail to advance to Phase III. This is the trial phase where the rubber meets the road. Theoretical promise collides with biological reality.

Phase II in the Peptide Community

Most peptides used in the community have no Phase II trials. Some have small pilot studies (Phase II-like, but without the formal regulatory structure). BPC-157 has two Phase II-equivalent trials in inflammatory bowel disease (both small, both showing some benefit, neither published in major peer-reviewed journals). These studies provided the human efficacy signal that generated community interest, but they did not establish efficacy in a rigorous, generalizable way. They certainly did not establish efficacy for the musculoskeletal injuries (tendon, ligament, muscle) that BPC-157 users report using it for.

The absence of Phase II trials for most peptides is the critical gap. It is also the gap that cannot easily be closed by compounding pharmacies. Phase II trials require patient recruitment, careful monitoring, statistical analysis, regulatory coordination, and publication in peer-reviewed journals. They cost $2–5 million or more.

↑ Back to top

Phase III: Pivotal Trials and Proof of Efficacy

Phase III is the evidence that regulators and physicians trust most. These are large, randomized, controlled trials—often multisite, often in patient populations that reflect real-world use.

Phase III Design

Phase III trials are powered to detect a clinically meaningful effect, not just a statistically significant one. They typically include 1,000–3,000 or more patients, randomized to the investigational drug, placebo, or an existing standard-of-care treatment. Randomization prevents bias. Blinding (when possible) prevents expectations from influencing outcomes. Sites are spread geographically to ensure the results generalize.

The endpoints are clinical—not just biomarker changes, but actual health outcomes. Does the drug reduce hospitalizations? Does it improve function? Does it reduce symptoms in a way that patients notice?

Phase III trials cost hundreds of millions of dollars. They take years to complete. They are the final evidence gate before FDA approval.

Phase III for GLP-1 Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have extensive Phase III trial data. For semaglutide, the SUSTAIN trials (Semaglutide Unabated Superiority versus Comparator of Insulin and Lantus) tested the drug in type 2 diabetes across multiple doses and multiple comparators. For weight loss (the indication driving recent demand), the SELECT trial tested tirzepatide’s effects on cardiovascular outcomes in obese and overweight patients.

These trials enrolled thousands of patients, tracked them for months to years, and measured health outcomes. The data were published in major journals (New England Journal of Medicine, Lancet, etc.). Regulatory agencies reviewed them. Physicians can read them.

This is why semaglutide and tirzepatide have Tier 1 evidence on Peptidings. They completed the entire pipeline: preclinical data, Phase I safety data, Phase II efficacy data in patients, and Phase III pivotal trials with large populations and clinical endpoints.

↑ Back to top

NDA/BLA Review: FDA Evaluation

Once Phase III is complete, a company submits either a New Drug Application (NDA) for small molecules or a Biologics License Application (BLA) for peptides and proteins. This application contains:

The entire dataset—All preclinical data, all clinical trial data, all manufacturing data, all safety data, all toxicology data. Thousands of pages.

A proposed labeling—The prescribing information that will accompany the drug. This includes indications, dosing, warnings, contraindications, and adverse reaction frequency.

Manufacturing details—How the drug will be made at scale, quality control procedures, stability data.

The FDA assigns a review priority:

• Standard review—10 months
• Priority review—6 months

The FDA can also ask for additional data (Requests for Additional Information, or RAIs), which extend the timeline.

During the review, the FDA may convene an Advisory Committee—a panel of independent experts (physicians, statisticians, patient advocates) who review the data and advise the FDA. Advisory Committee meetings are public. Stakeholders can attend and submit written comments.

The FDA’s job is to determine whether the benefits of the drug outweigh the risks for the indicated population, and whether the manufacturing is consistent and safe.

FDA Approval Standards

The FDA does not require certainty. It requires “substantial evidence” that the drug is safe and effective. For drugs treating serious conditions with no effective alternatives, the bar is lower than for drugs treating non-serious conditions with existing treatments. For drugs causing severe adverse effects, the evidence of benefit must be higher.

For most medications, substantial evidence means multiple well-controlled trials (or one large definitive trial) showing a clinically meaningful benefit.

Once the FDA approves a drug, it receives a prescription label that specifies the approved indication, the recommended dose, the contraindications, and the known adverse effects. Marketing must conform to the approved label. Off-label use is legal (physicians can prescribe drugs for any indication they believe is appropriate), but the company cannot market off-label uses.

↑ Back to top

Phase IV: Post-Marketing Surveillance

Approval is not the end of safety monitoring. Phase IV consists of ongoing surveillance after the drug is on the market.

Companies must report serious adverse events to the FDA. The FDA monitors for adverse event reports submitted by patients, physicians, and pharmacies. Rare adverse effects that did not emerge in clinical trials sometimes appear once millions of people are taking the drug. The FDA can issue warnings, require additional monitoring, or in severe cases, withdraw approval.

Large simple trials can be conducted post-approval to test new indications or to answer questions that emerged after launch.

↑ Back to top

The Timeline and Cost Reality

The average drug takes 10–15 years from discovery to approval. This is not an exaggeration. It is documented.

The timeline includes:

• 3–6 years of preclinical work
• 1–3 years to design the IND application and conduct Phase I
• 2–3 years for Phase II
• 2–3 years for Phase III
• 1–2 years for FDA review

These timelines overlap somewhat, but not completely. While Phase II is enrolling, Phase I is concluding, but the preclinical work is already done. While Phase III is enrolling, Phase II data analysis is happening, but Phase I is history.

The cost averages $1–2 billion per approved drug, including:

• All failed candidates (the 90% that don’t make it)
• Preclinical research and development
• IND application preparation
• Clinical trial costs (sites, monitoring, analysis)
• Regulatory submissions
• Manufacturing scale-up
• Corporate overhead

This is the cost to bring one drug to market. Most pharmaceutical companies run multiple parallel programs to distribute this risk.

Why This Matters for Peptides

The timeline and cost create an economic barrier. A compounding pharmacy or a small research company cannot afford to take a peptide through the entire FDA pipeline. The financial risk is too high, and the regulatory burden is too great.

This is why peptides exist in a gray zone. They are synthesized and sold by compounding pharmacies. They may have preclinical data. Some have small pilot studies (Phase II-equivalent). None have completed the Phase III pipeline.

The gap is not new. This is how peptides have always operated in the community. What is new is that peptides like ipamorelin, TB-500, and BPC-157 have accumulated enough anecdotal use and enough small pilot studies that the community treats them as effective. But the formal evidence stops at Phase I safety data or small open-label efficacy studies.

↑ Back to top

Where Peptides Sit in the Pipeline

GLP-1 agonists (semaglutide, tirzepatide)—Completed the entire pipeline. Phase III trials with thousands of patients. FDA-approved. Tier 1 evidence.

Ipamorelin—Preclinical data plus one Phase I study. That’s it. No Phase II or Phase III. Tier 4 evidence.

BPC-157—Preclinical data (extensive animal model data) plus two small Phase II-like trials in IBD (not controlled). No Phase II dose-ranging study. No Phase III. Tier 3 evidence (some human data, but limited control and limited scope).

TB-500 (thymosin beta-4)—Preclinical data. Topical formulation has some Phase II data for wound healing (limited). Injectable formulation has almost no human trial data. Tier 3 or Tier 4 depending on indication and formulation.

Epitalon (epithalon)—Preclinical data. One small Phase II study (published) in Russia, testing effects on vision in age-related conditions. Limited replication. Tier 3 evidence.

GHK-Cu (copper peptide)—Topical formulation has some Phase II data (limited). Injectable formulation has minimal human trial data. Tier 3 or Tier 4 depending on indication.

Cerebrolysin—Preclinical data. Multiple Phase II trials in stroke and cognitive decline (mostly in Europe and Russia). Some evidence of benefit, but trials are heterogeneous and not all published in English-language peer-reviewed journals. Tier 2 or Tier 3 depending on indication.

The pattern is clear: most peptides stop somewhere between Phase I and Phase II. Very few have Phase III data. None except the GLP-1 agonists have completed the full FDA approval pipeline.

↑ Back to top

Why Compounds Get Stuck

The reasons compounds never advance past preclinical or early Phase I:

Market size—For a rare disease or a small patient population, the market may not be large enough to justify $1–2 billion in development costs. A peptide that works beautifully for a condition affecting 10,000 people may never be developed formally because the revenue doesn’t justify the investment.

Patent considerations—If a peptide is based on a natural sequence (like thymosin beta-4 or ipamorelin) and the patent has expired or never existed, a company cannot recoup development costs through exclusivity. Why spend a billion dollars to develop a drug that anyone can manufacture once it’s approved?

Regulatory pathway confusion—Peptides are biologics, not small molecules. The regulatory pathway for biologics is different from small molecules. Manufacturers sometimes take different regulatory approaches (e.g., pursuing compounding pharmacy status rather than FDA approval), which avoids the full pipeline but also prevents accumulation of formal evidence.

Compounding pharmacy alternative—If a peptide can be synthesized and sold through compounding pharmacies without FDA approval, there is no financial incentive to pursue FDA approval. The compounding pathway is faster and cheaper. It is also unregulated, which means no formal safety surveillance, no standardized dosing, no manufacturer accountability.

This is not a conspiracy or a gap in the system. It is a rational economic decision by manufacturers. But it has a consequence: the peptides most accessible to consumers are exactly the peptides least likely to have formal clinical evidence.

↑ Back to top

How This Maps to Peptidings Evidence Tiers

Peptidings’ evidence tier system reflects the pipeline:

Tier 1—FDA-approved drugs with Phase III trial data. Complete pipeline. Semaglutide, tirzepatide. The gold standard.

Tier 2—Phase II and Phase III data without FDA approval, or extensive Phase II data from multiple sites/countries with consistent results. Cerebrolysin (in some countries/indications). Some reformulated peptides that have done rigorous efficacy trials.

Tier 3—Phase I safety data plus some Phase II data, or multiple smaller efficacy studies with some controls. BPC-157 (2 pilot trials in IBD). Topical GHK-Cu (Phase II wound healing data). Ipamorelin barely qualifies (Phase I only, no Phase II). Data is present but limited in scope or rigor.

Tier 4—Preclinical data only, or Phase I safety data with no efficacy data. Most peptides used in the community fall here. Ipamorelin, TB-500 (injectable), most others. The rationale is clear: we know safety was tested in a controlled way, but we don’t know efficacy was tested in humans at all.

The tiers are not moral judgments. They are map positions on the pipeline. A Tier 4 compound is not useless. It is simply at an early stage of the pipeline. The question is whether you are comfortable using a compound at that stage.

↑ Back to top

↑ Back to top

FAQ

Related Guides

• Evidence Levels Explained (forthcoming)—Detailed breakdown of Peptidings’ five-tier evidence system
• How to Read a Study (forthcoming)—Evaluating study design, population, and outcomes
• Pharmacokinetics and Pharmacodynamics: What PK/PD Actually Means (forthcoming)—Understanding how bodies process drugs
• FDA Categories and WADA Status: What the Labels Mean (forthcoming)—Regulatory standing of common peptides

↑ Back to top

Conclusion

The path from lab bench to pharmacy shelf is long, expensive, and designed to filter out compounds that don’t work or are unsafe. Most compounds fail. The ones that make it through have been tested thousands of times—in cells, in animals, in healthy humans, in patient populations, and in large controlled trials.

This is why the evidence tiers matter. A compound with Tier 1 evidence has completed the pipeline. It is approved for a specific indication. Its safety has been monitored in millions of people. A compound with Tier 4 evidence has preclinical data—which is genuinely impressive sometimes—but has never been tested in a controlled way in humans for the conditions people use it for.

Neither of these facts is secret. The compounds most used in the peptide community (ipamorelin, BPC-157, TB-500, GHK-Cu) have transparently incomplete evidence. They exist in the gap between the lab and the formal pipeline. The question is not whether the gap exists. The question is whether you are comfortable using a compound in that gap, and whether you understand what “gap” means.

That understanding begins with understanding the pipeline. This guide is meant to provide it.

↑ Back to top

Evidence Framework Summary

This guide makes general reference to FDA pipeline statistics, attrition rates, timeline data, and drug development costs. These figures are sourced from:

• FDA public information on drug approval timelines and attrition rates
• Pharmaceutical Research and Manufacturers of America (PhRMA) research on development costs
• Peer-reviewed literature on drug development processes (published in journals like Nature Reviews Drug Discovery, Drug Discovery Today, Clinical Therapeutics)
• ClinicalTrials.gov data on trial phases and timelines

Peptide-specific evidence tier assignments (e.g., ipamorelin as Tier 4, semaglutide as Tier 1, BPC-157 as Tier 3) are based on Peptidings’ master evidence evaluation framework and are consistent with the evidence tier definitions in Evidence Levels Explained (forthcoming).

The specific trial citations (Gobburu et al. Phase I ipamorelin, SUSTAIN trials for semaglutide, SURPASS and SURMOUNT trials for tirzepatide) are accurate but are presented as examples rather than comprehensive literature reviews. Readers interested in specific evidence for specific compounds should consult the compound articles on Peptidings.

↑ Back to top

---